Awaiting development: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Area of interest

Area of interest

Type

Type

Guidance programme

Showing 1 to 10 of 336

TitleType
10395 - Aprocitentan for treating resistant hypertension TS ID 10395Technology appraisal guidance
12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years ID6510Technology appraisal guidance
Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095Technology appraisal guidance
Abdominal aortic aneurysmQuality standard
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]Technology appraisal guidance
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]Technology appraisal guidance
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]Technology appraisal guidance
Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232Technology appraisal guidance
AcneQuality standard
Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy [ID6354]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All